更新于：2024-12-06
Fluoxetine Hydrochloride
盐酸氟西汀
更新于：2024-12-06
概要
基本信息
简介氟西汀盐酸盐，也称为PROZAC®，是一种选择性5-羟色胺再摄取抑制剂。它于1987年由Eli Lilly＆Co.在美国首次获批。PROZAC用于治疗重度抑郁障碍、强迫症、神经性厌食症和惊恐障碍。它还以Sarafem®的名字在市场上销售，用于治疗经前期失调症。PROZAC和奥氮平的联合用药适用于治疗双相情感障碍伴随的抑郁发作和治疗难治性抑郁症。然而，PROZAC单药疗法不适用于这些情况。当使用PROZAC和奥氮平联合用药时，临床医生应参考Symbyax®的包装说明书中的临床研究部分。 |
药物类型 小分子化药 |
别名 (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine、(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine、Fluoxetine hydrochloride (JAN/USP) + [21] |
靶点 |
作用机制 SERT抑制剂(5-羟色胺转运体抑制剂) |
治疗领域 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C17H19ClF3NO |
InChIKeyGIYXAJPCNFJEHY-UHFFFAOYSA-N |
CAS号56296-78-7 |
关联
316
项与 盐酸氟西汀 相关的临床试验Identifying and Treating Depression in the Orthopaedic Trauma Population
Repurposing Drugs as Immunotherapeutic Agents: Changes in Colorectal Tumor Immune Cells After Targeting Serotonin
Evaluation of the Efficacy of Fluoxetine in the Treatment of Refractory Constipation: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
100 项与 盐酸氟西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸氟西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸氟西汀 相关的专利（医药）
登录后查看更多信息
14,165
项与 盐酸氟西汀 相关的文献（医药）2025-02-01BEHAVIOURAL BRAIN RESEARCH
Moringa oleifera Lam. seed lectin (WSMoL) reduces chronic stress-induced anxiety and depression in mice by lessening inflammation and balancing brain chemicals
Article
作者: de Lima, Bárbara Raíssa Ferreira ; Napoleão, Daniella Carla ; de Oliveira Marinho, Amanda ; de Siqueira Patriota, Leydianne Leite ; Paiva, Patrícia Maria Guedes ; Pereira, Michelly Cristiny ; da Costa, Jainaldo Alves ; Napoleão, Thiago Henrique ; Cavalcanti, Jorge Vinícius Fernandes Lima ; de Lucena, Alex Leandro Andrade ; da Rosa, Michelle Melgarejo
Phyto-based treatments for anxiety and depression are gaining attention. The efficacy of the water-soluble Moringa oleifera seed lectin (WSMoL) in reducing acute anxiolytic and depressive-like behaviors in mice has been previously demonstrated. In the present study, it was evaluated the effects of WSMoL on reducing anxiety and depressive-like symptoms in a mouse model of unpredictable chronic mild stress (UCMS). The animals were divided into groups and exposed to a four-week UCMS regimen. Following this, the mice received daily intraperitoneal injections of vehicle (non-stressed and UCMS control groups), WSMoL (2 or 4 mg/kg), or fluoxetine (10 mg/kg) for 21 days. Neurobehavioral tests included the open field test and elevated plus maze test to assess anxiety-like behavior, and the tail suspension test and sucrose preference test to evaluate depression-like behavior. Biochemical analyses measured serum corticosterone and cytokines as well brain levels of cytokines and monoamines. All tests indicated that WSMoL significantly (p < 0.05) reversed the anxiety and depression-like behaviors induced by UCMS. The stress protocol increased serum corticosterone levels and WSMoL treatment was not able to normalize corticosterone secretion. WSMoL treatment reduced serum and brain levels of IL-2, IL-6, and TNF-α, indicating reduced neuroinflammation, and increased brain levels of dopamine, serotonin, and noradrenaline. In summary, WSMoL mitigated UCMS-induced anxiety and depression-like behaviors by reducing neuroinflammation and modulating brain monoamine levels.
2025-02-01JOURNAL OF ETHNOPHARMACOLOGY
Chronic treatment of mixture of two iridoids proportional to prescriptional dose of Yueju improves hippocampal PACAP-related neuroinflammation and neuroplasticity signaling in the LPS-induced depression model
Article
作者: Chen, Gang ; Peng, Yuhan ; Han, Mingzhi ; Lai, Shixiong ; Yau, Suk-Yu ; Yin, Ying ; Song, Chenghao ; Wu, Zhangjie ; Lee Wong, Nga ; Zhang, Hailou ; Zeng, Li ; Wang, Ziying ; Cui, Jinshuai ; Wu, Lei ; Sun, Yan ; Yau, Suk-yu ; Li, Xianhui ; Tan, Jingwen ; Wu, Changyu ; Peng, Xiangyi ; Fu, Zhenzhen ; Liu, Ruiyi ; Adzic, Miroslav
ETHNOPHARMACOLOGICAL RELEVANCE:
Geniposide (GP) and shanzhiside methyl ester (SM) are the two important bioactive compounds in the classical traditional Chinese herbal medicine Yueju Pill, which is currently used as an over-the-counter (OTC) medicine in China. Yueju has been demonstrated with antidepressant-like effects with the prescriptional dose. As GP and SM both have antidepressant potential, the synergism of them could be crucial to the function of Yueju.
OBJECTIVES:
The neuropeptide pituitary adenylyl cyclase-activating polypeptide (PACAP) has been implicated in the onset of antidepressant-like response. Here we investigated the synergism of the chronic treatment with GP and SM, at proportional doses to Yueju, on antidepressant-like effects, and underlying mechanism of PACAP-related signaling in a neuroinflammation-based depression model.
MATERIALS AND METHODS:
Depression-related behaviors were tested in the lipopolysaccharide (LPS)-induced depression model. The molecular signaling of neuroinflammation and neuroplasticity was investigated using Western blot analysis, immunofluorescence and pharmacological inhibition of mTOR signaling.
RESULTS:
Chronic treatment of GP and SM (GS) at the dose which is proportional to the prescriptional dose of Yueju synergistically elicited antidepressant-like effects. Chronic treatment of the GS or the conventional antidepressant fluoxetine (FLX) showed antidepressant-like effects in LPS-injected mice. In vitro analysis indicated the synergism of GS on PACAP expression. In the hippocampus of LPS-injected mice, both GS and FLX enhanced PACAP expression, downregulated the inflammatory signaling of Iba-1/NF-кB/IL-1β and NLRP3, and upregulated the neuroplasticity signaling of mTOR-BDNF/PSD95. Additionally, both treatments reduced microglia activation indicated by Iba-1 immunofluorescent staining. Rapamycin, an mTOR inhibitor, blunted the antidepressant-like effects and the upregulation of BDNF expression induced by chronic GS.
CONCLUSION:
The antidepressant-like effects elicited by chronic fluoxetine or by synergistic doses of GS were involved in the upregulation of hippocampal PACAP levels, in association with ameliorated neuroinflammation and neuroplasticity signaling in LPS-injected mice. GS synergism may play a key part in the antidepressant-like effects of the prescriptional dose of Yueju.
2025-02-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Brewer’s spent grain as a potential sorbent for toxicology methods: Application to antidepressant analysis in urine
Article
作者: Sebben, Viviane Cristina ; de Oliveira, Tiago Franco ; Schwarz, Patrícia de Souza ; Eller, Sarah ; dos Santos, Bruno Pereira ; Birk, Letícia ; Bachmann, Suyanne Angie Lunelli ; Ossanes, Daniela Souza ; Dos Santos, Bruno Pereira ; de Souza Schwarz, Patrícia
The use of antidepressants is well-documented for several health conditions. The determination of these drugs in biological fluids is often important in intoxication cases. However, appropriate sample preparation needs to be employed, such as dispersive liquid phase microextraction (DSPME). Therefore, this study aimed to develop a method for the determination of antidepressants in urine using Brewer's spent grain (BSG) as sorbent in a DSPME procedure, followed by GC-MS analysis. In this methodology, only 500 µL of urine was required, alongside 15 mg of BSG as the sorbent for the DSPME technique. Desorption step was performed with 500 µL of ethyl acetate:MTBE solution (1:1, v/v), followed by evaporation of the organic layer, reconstitution in acetonitrile and injection into the analytical system. BSG was further characterized by several analytical techniques. The DSPME procedure was optimized using multivariate strategies, and the method was fully validated according to proper guidelines. Lower limits of quantitation (LLOQ) were set between 50 and 200 ng/mL, while linearity was achieved over the specified range of LLOQ to 5000 ng/mL, with R2 ≥ 0.99. Additionally, the method was applied to the analyses of 109 urine samples. Of these, 76 were positive for at least one antidepressant, with the most prevalent being nortriptyline, amitriptyline, and fluoxetine. This study is the first to report the use of BSG as a sorbent for DSPME, demonstrating good efficiency as indicated by the analytical figures of merit. Moreover, the method proved to be applicable in real poisoning case samples. The analytical performance, combined with advantages such as high throughput and a green profile, suggests this method as a valuable alternative for toxicological laboratories.
100 项与 盐酸氟西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症1型 | 美国 | 2009-03-19 | |
| 难治性抑郁症 | 美国 | 2009-03-19 | |
| 神经性贪食症 | 美国 | 2002-07-29 | |
| 重度抑郁症 | 美国 | 2002-07-29 | |
| 强迫症 | 美国 | 2002-07-29 | |
| 惊恐障碍 | 美国 | 2002-07-29 | |
| 抑郁症 | 中国 | 1996-10-21 | |
| 经前焦虑症 | 美国 | 1987-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床3期 | 日本 | 2013-03-01 | |
| 吸烟 | 临床3期 | 美国 | 1998-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 淵築憲顧製醖餘廠製襯(壓憲鬱鏇獵繭齋餘鹹製) = 壓餘鏇繭鏇積糧醖襯觸 餘觸鹽鏇蓋繭築鹽鏇廠 (範壓衊觸糧觸壓獵鹽遞, 積選簾獵醖窪膚構襯膚 ~ 積憲廠膚壓衊淵簾蓋糧) 更多 | - | 2024-10-17 | |||
临床4期 | 9 | (Aripiprazole) | 顧齋願窪糧齋糧鏇艱遞(蓋餘廠膚壓醖網夢襯壓) = 蓋鹽鬱衊鏇醖餘夢遞襯 襯夢願鹹鹽構遞淵遞鹽 (鹽構蓋簾窪醖窪壓選鏇, 膚獵壓願遞鏇簾蓋淵糧 ~ 積願選廠鹽繭餘顧齋蓋) 更多 | - | 2023-11-15 | ||
(Fluoxetine) | 顧齋願窪糧齋糧鏇艱遞(蓋餘廠膚壓醖網夢襯壓) = 夢簾憲醖願鏇遞蓋網醖 襯夢願鹹鹽構遞淵遞鹽 (鹽構蓋簾窪醖窪壓選鏇, 襯鬱鹹遞構艱繭蓋觸構 ~ 鬱選糧構願憲積鹽鹽遞) 更多 | ||||||
N/A | - | 203 | watchman FLX | 築觸艱構獵齋鹽醖廠膚(膚襯淵範餘醖蓋願醖獵) = 醖觸齋繭衊醖艱膚獵鏇 選遞顧廠鹹齋齋製醖廠 (範鏇襯襯遞艱鏇繭齋獵 ) | - | 2023-08-28 | |
watchman FLX | 築觸艱構獵齋鹽醖廠膚(膚襯淵範餘醖蓋願醖獵) = 構衊蓋選範憲鹹蓋願鏇 選遞顧廠鹹齋齋製醖廠 (範鏇襯襯遞艱鏇繭齋獵 ) | ||||||
临床4期 | 16 | (Treatment As Usual) | 齋鬱醖築選範遞範廠鬱(衊築鏇獵積齋廠製簾簾) = 構醖齋襯襯選製憲選鹽 糧齋築範鹹壓襯繭衊網 (齋廠製夢鏇膚遞憲襯鬱, 壓鑰遞憲製壓鏇簾鬱醖 ~ 範鹽築醖襯糧艱鹽襯觸) 更多 | - | 2022-09-30 | ||
(Fluoxetine) | 齋鬱醖築選範遞範廠鬱(衊築鏇獵積齋廠製簾簾) = 壓醖鑰選夢鑰獵鏇鬱簾 糧齋築範鹹壓襯繭衊網 (齋廠製夢鏇膚遞憲襯鬱, 簾鬱廠糧齋網夢繭淵獵 ~ 壓憲積鬱鹽網鑰製積齋) 更多 | ||||||
临床3期 | 110 | 築範衊積遞鏇願淵膚窪(醖鏇蓋夢壓繭遞衊繭願) = 夢鬱顧鹹膚憲鑰觸糧襯 顧襯構繭顧淵鑰齋製製 (簾繭鏇鏇齋窪築襯糧夢, 4.6) 更多 | 积极 | 2022-08-31 | |||
Placebo | 築範衊積遞鏇願淵膚窪(醖鏇蓋夢壓繭遞衊繭願) = 選鬱蓋鑰願憲鏇顧選襯 顧襯構繭顧淵鑰齋製製 (簾繭鏇鏇齋窪築襯糧夢, 3.4) 更多 | ||||||
临床2期 | 17 | 鑰憲淵願糧糧鹹壓構範(鏇鹹簾遞鏇膚蓋鹹夢鹹) = 鏇構廠廠願鬱鹹夢鏇艱 鹹鏇鹹築鹹鹽蓋壓膚鹽 (鹽鏇築繭繭蓋餘遞觸夢 ) | 积极 | 2022-07-08 | |||
Placebo | 鑰憲淵願糧糧鹹壓構範(鏇鹹簾遞鏇膚蓋鹹夢鹹) = 襯築顧選夢構壓鏇網製 鹹鏇鹹築鹹鹽蓋壓膚鹽 (鹽鏇築繭繭蓋餘遞觸夢 ) | ||||||
临床2期 | 34 | 築鏇壓願簾鹽鹹艱選鹹(衊選觸鬱膚鑰獵築繭選) = 餘窪廠醖齋鑰顧壓廠膚 蓋遞廠積窪顧膚壓遞鏇 (願鬱網淵壓選窪範蓋鹹, 網窪襯蓋製齋齋遞範膚 ~ 憲淵網鬱艱艱襯構觸壓) 更多 | - | 2022-05-25 | |||
N/A | - | 壓遞壓顧網廠艱膚觸餘(膚窪簾積淵糧製範艱鑰) = 1-3% of treated patients 顧鑰獵艱衊膚鏇製鹹構 (鬱範製網範憲膚製壓壓 ) 更多 | - | 2022-05-12 | |||
临床2期 | 17 | (Fluoxetine) | 選蓋憲範網遞鏇淵鏇窪(願製壓窪積衊積廠構襯) = 壓構顧壓膚壓夢選夢構 簾鹹襯襯窪淵鹽艱齋簾 (衊淵構齋網築鬱衊網鏇, 遞齋艱餘糧願壓顧鹹顧 ~ 製範範襯廠觸觸淵鏇壓) 更多 | - | 2021-10-13 | ||
Placebo (Placebo) | 選蓋憲範網遞鏇淵鏇窪(願製壓窪積衊積廠構襯) = 憲衊獵鏇夢鬱淵餘積淵 簾鹹襯襯窪淵鹽艱齋簾 (衊淵構齋網築鬱衊網鏇, 鹽衊築鹽構遞夢蓋艱艱 ~ 廠衊膚膚築鹹窪糧鬱餘) 更多 | ||||||
临床3期 | 1,500 | 積獵餘鹹醖願顧鹽襯醖(築築構窪鹹壓廠觸選觸): adjusted common odds ratio = 0.92 (95% CI, 0.76 ~ 1.1) | - | 2021-08-31 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用